Literature DB >> 15986403

Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease.

Heinz Zoller1, Ian McFarlane, Igor Theurl, Sylvia Stadlmann, Elizabeta Nemeth, David Oxley, Tomas Ganz, David J Halsall, Timothy M Cox, Wolfgang Vogel.   

Abstract

Ferroportin disease (hemochromatosis type 4) is a recently recognized disorder of human iron metabolism, characterized by iron deposition in macrophages, including Kupffer cells. Mutations in the gene encoding ferroportin 1, a cellular iron exporter, are responsible for this iron storage disease, inherited as an autosomal dominant trait. We present clinical, histopathological, and radiological findings in a family with the most common ferroportin mutation, V162del. In the index case, the disorder is characterized by abundant deposition of hemosiderin in all tissues investigated (mesenteric lymph node, liver, gastric and duodenal mucosa, and also in squamous cell carcinoma of the lung). The radiological findings indicated the presence of excess iron in bone marrow and spleen. Despite a significant burden of iron, no features of chronic liver disease were found in affected members of the family, including individuals aged up to 80 years. Hyperferritinemia greater than 1,000 microg/L was a penetrant biochemical finding before the second decade in life and was associated with significantly increased serum concentrations of pro-hepcidin that correlated positively with urinary hepcidin concentrations. In conclusion, the systemic iron burden in ferroportin disease is not a sufficient cause for chronic liver disease. In patients with most, but not all, ferroportin mutations, retention of iron in macrophages of the liver and other organs may protect against damage to parenchymal cells. Finally, macrophage iron storage in ferroportin disease is associated with elevated serum pro-hepcidin levels.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15986403     DOI: 10.1002/hep.20775

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  19 in total

1.  Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders.

Authors:  Yoshibumi Kaneko; Hiroaki Miyajima; Alberto Piperno; Naohisa Tomosugi; Hisao Hayashi; Natsuko Morotomi; Ken-ichi Tsuchida; Takaaki Ikeda; Akihisa Ishikawa; Yusuke Ota; Shinya Wakusawa; Kentaro Yoshioka; Satoshi Kono; Sara Pelucchi; Ai Hattori; Yasuaki Tatsumi; Toshihide Okada; Masakazu Yamagishi
Journal:  J Gastroenterol       Date:  2010-06-09       Impact factor: 7.527

2.  Serum hepcidin: a novel diagnostic tool in disorders of iron metabolism.

Authors:  Gaetano Bergamaschi; Laura Villani
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

3.  Iron overload patients with unknown etiology from national survey in Japan.

Authors:  Katsuya Ikuta; Mayumi Hatayama; Lynda Addo; Yasumichi Toki; Katsunori Sasaki; Yasuaki Tatsumi; Ai Hattori; Ayako Kato; Koichi Kato; Hisao Hayashi; Takahiro Suzuki; Masayoshi Kobune; Miyuki Tsutsui; Akihiko Gotoh; Yasuo Aota; Motoo Matsuura; Yuzuru Hamada; Takahiro Tokuda; Norio Komatsu; Yutaka Kohgo
Journal:  Int J Hematol       Date:  2016-11-15       Impact factor: 2.490

4.  A novel monoclonal antibody immunoassay for the detection of human serum hepcidin.

Authors:  Peggy Schwarz; Pavel Strnad; Guido von Figura; Alfred Janetzko; Pierre Krayenbühl; Guido Adler; Hasan Kulaksiz
Journal:  J Gastroenterol       Date:  2010-12-07       Impact factor: 7.527

5.  Wild-type and mutant ferroportins do not form oligomers in transfected cells.

Authors:  Ana Sofia Gonçalves; Françoise Muzeau; Rand Blaybel; Gilles Hetet; Fathi Driss; Constance Delaby; François Canonne-Hergaux; Carole Beaumont
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857

Review 6.  Studying disorders of vertebrate iron and heme metabolism using zebrafish.

Authors:  Lisa N van der Vorm; Barry H Paw
Journal:  Methods Cell Biol       Date:  2016-12-09       Impact factor: 1.441

7.  An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.

Authors:  Paul J Schmidt; Iva Toudjarska; Anoop K Sendamarai; Tim Racie; Stuart Milstein; Brian R Bettencourt; Julia Hettinger; David Bumcrot; Mark D Fleming
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

8.  The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease.

Authors:  Irene E Zohn; Ivana De Domenico; Andrew Pollock; Diane McVey Ward; Jessica F Goodman; Xiayun Liang; Amaru J Sanchez; Lee Niswander; Jerry Kaplan
Journal:  Blood       Date:  2007-02-08       Impact factor: 22.113

Review 9.  Non-HFE haemochromatosis.

Authors:  Daniel-F Wallace; V-Nathan Subramaniam
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

Review 10.  Hepcidin modulation in human diseases: from research to clinic.

Authors:  Alberto Piperno; Raffaella Mariani; Paola Trombini; Domenico Girelli
Journal:  World J Gastroenterol       Date:  2009-02-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.